Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays by Hoofnagle, Andrew N. et al.
Recommendations for the generation, quantification, storage 
and handling of peptides used for mass spectrometry-based 
assays
A full list of authors and affiliations appears at the end of the article.
Keywords
calibrators; internal standards; lc-ms/ms; mass spectrometry; peptide; reference material
Introduction
The Clinical Proteomic Tumor Analysis Consortium (1) (CPTAC) of the National Cancer 
Institute (NCI) is a comprehensive and coordinated effort to accelerate the understanding of 
the molecular basis of cancer through the application of robust technologies and workflows 
for the quantitative measurements of proteins. The Assay Development Working Group of 
the CPTAC Program aims to foster broad uptake of targeted mass spectrometry-based assays 
employing isotopically labeled peptides for confident assignment and quantification, 
including multiple reaction monitoring (MRM; also referred to as Selected Reaction 
Monitoring), parallel reaction monitoring (PRM), and other targeted methods.
Guidelines for reagents and methods will ensure that targeted measurements of peptides are 
of high quality, distributable, and fit-for-purpose to quantify analytes in the intended matrix 
(plasma, serum, cells, and tissues). Towards these goals, we have: (i) coordinated a 
consensus approach to outline recommendations for the development of different classes of 
targeted mass spectrometry (MS)-based assays using a fit-for-purpose approach (2), (ii) 
launched the CPTAC Antibody Portal (3) (antibodies.cancer.gov) to facilitate the production, 
characterization and distribution of renewable affinity reagents to the community in order to 
support protein/peptide measurement and analysis, and (iii) launched and begun to populate 
the CPTAC Assay portal (4) (https://assays.cancer.gov/) to disseminate highly characterized 
targeted MS-based assays to the community, via access to standard operating protocols 
(SOP), reagents, and assay characterization data.
Within workflows designed to quantify protein-derived biomarkers by proteolytic digestion 
and LC-MS/MS, synthetic peptides are often used in three ways: (1) stable isotope-labeled 
internal standard peptides with the same sequence as the analyte of interest are spiked into 
the digest and help ensure that the correct peptide is being identified and quantified (i.e., 
they have the same retention time, same secondary structure, and similar fragmentation 
pattern as the endogenous analyte), (2) stable isotope-labeled internal standard peptides help 
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normalize sample-specific ion suppression and are used in the calculation of a peak area 
ratio (i.e., the ratio of the endogenous analyte chromatographic peak area to that of the 
internal standard), and (3) unlabeled or labeled peptides can be used to generate calibration 
materials for the quantification of peptide in proteolytic digests of complex protein mixtures 
(i.e., determining the peak area ratio at known concentrations of analyte in a relevant 
matrix). Well-characterized peptides, along with detailed standard operating procedures for 
proteolysis and sample preparation, are necessary to harmonize peptide-based assays (4). In 
the clinical laboratory, calibration materials are more commonly based on intact proteins in a 
relevant matrix, which may be useful in further harmonizing the quantification of proteins 
between laboratories (5-7). Of note, in addition to isotope-labeled internal standard peptides, 
isotope-labeled extended peptides (also called “winged” peptides, which include a 
proteolytic digestion site) and recombinant proteins can be used to compensate for the 
additional variability due to digestion (5, 6). The latter will be increasingly important, 
particularly in clinical applications, as properly folded recombinant isotope-labeled proteins 
become more widely commercially available.
Once proteolytically digested, the quantification of peptides in the sample can be easily 
facilitated by using stable isotope-labeled peptides as internal standards and traditional LC-
MS/MS methods. Most commonly trypsin is used for proteolysis, resulting in arginine or 
lysine at the C-terminus. As a result of the variability amongst peptides in their recovery and 
stability following proteolytic digestion, especially between samples and sample types, as 
well as the isoform complexity of human proteins, the peak area ratio or measured 
concentration of any peptide may not accurately reflect the concentration of any given intact 
protein or isoform. Importantly, the same potential limitation also applies when using 
isotopically-labeled proteins as internal standards. While potentially providing improved 
precision and less bias than labeled peptides in quantitative MS-based assays (8, 10), 
differences in the repertoire of modifications (e.g., phosphate, carbohydrate, ubiquitin, etc.) 
on amino acid residues near enzymatic cleavage sites, for example, can alter digestion and 
recovery of desired analyte peptides from internal standard proteins. Regardless of the 
internal standard chosen, with a detailed, reproducible, and robust standard operating 
procedure for sample preparation and digestion in place, it is possible that the peak area ratio 
of a liberated peptide could be precise enough to be a biomarker without calibration to a 
protein concentration.
Therefore, the goal of establishing recommendations for peptide-based, targeted MS 
measurements is to achieve precise, relative quantification that can be harmonized across 
laboratories, increasing the replicability of research and enabling the aggregation of data 
across experiments and laboratories, as well as enabling the robust quantification of peptides 
and proteins in clinical laboratories. In addition to the need for transparency in digestion 
methods and sample preparation (i.e., freely available standard operating procedures) (4, 
11), the major challenges to achieving this analytical bar are: (i) selection of peptides that 
can be measured with high precision and repeatability in the matrix of interest, (ii) 
generating well-characterized, pure synthetic peptide internal standards and calibrators, (iii) 
determining the accurate concentration of pure synthetic peptide internal standards and 
calibrators, (iv) assurance of the quality (e.g. concentration, stability) of the peptide internal 
standards and calibrators in lyophilized form and in solution over time, during both storage 
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and handling, and (v) proper interpretation of peptide-based measurements. The purpose of 
this manuscript is to address these key components by aggregating recommendations, based 
on published studies and/or the consensus experiences of the authors. The use of “crude” 
peptides (that have limited or no purification or quantification but are far less expensive than 
purified peptides) is also discussed, and the limitations of their use for quantitative 
measurements are presented. The manuscript provides a thorough framework for proteomics 
researchers and an introduction towards clinical applications. Ideally, the recommendations 
included here provide a starting reference point for the production of formal guidelines and 
best practices in the future (e.g., from the Clinical Laboratory Standards Institute).
Criteria and process for selecting peptide analytes for targeted MS assays
Assays to measure protein concentration by proteolysis and LC-MS/MS (e.g. MRM) 
selectively quantify “proteotypic” (12) (typically tryptic) peptides that are unique to a single 
gene product or proteoforms (13) and that are observable by mass spectrometry. Because 
peptides vary greatly in their performance across many aspects (e.g. ease of synthesis, 
stability, solubility, recovery, responsiveness in the mass spectrometer) of targeted MS 
analysis, careful selection of peptide analytes is critical to developing the highest quality 
assays.
Peptide analytes can be selected using MS-based proteomic data or prediction algorithms 
(14-22). Selecting peptides from empirical MS data greatly increases the likelihood for 
success in developing a targeted MS-based assay, as the peptide analytes have been 
demonstrated to release from the protein of interest upon digestion and are detectable by 
MS. Candidate peptide analytes from proteins can be selected from either in-house or public 
empirical data. For the latter, numerous open source proteomic databases and data 
repositories exist [e.g. GPM (23), PRIDE (24), Peptide Atlas (25-27), PhosphoSitePlus 
(28)]. The use of spectral libraries, either generated with one's own MS/MS data or obtained 
from one of the online spectral library repositories, can greatly facilitate selection of the 
peptides (and the most intense ions) to target for quantification. Bioinformatic approaches 
can also be used to identify peptide sequences that can be theoretically formed upon 
proteolytic digestion and that may be useful for MS-based assay development. However, 
such tools are not as reliable as empirical MS/MS data, which remain the gold standard. In 
practice, a combination of the two approaches in an iterative manner is often used to hone 
the choice of the best peptide(s) as rapidly as possible.
A summary of criteria for peptide selection is presented in Table 1. Despite the above-
mentioned considerations, peptide selection is an empirical exercise that balances ideal 
characteristics with practical limitations. In some cases, due to the sequence of the protein of 
interest, it may be unavoidable to include peptides that do not meet all of these 
recommended criteria. Therefore these criteria are simply meant to be guidelines for peptide 
selection, and some relaxation of the inclusion criteria may be necessary to develop the 
MRM assay. For example, it may be impossible to exclude all cysteine and methionine 
residues. In such cases, the precursor and product mass-to-charge ratio (m/z) values should 
account for any potential oxidation and carbamidomethylation modifications (+16 and +57 
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Da, respectively). Additionally, selection of peptides to develop assays for phosphosite 
quantification is very constrained by the position and potential clustering of phosphosites.
Specifications for production and quality assurance of peptides
Once proteotypic peptides have been selected for assay development, the synthetic peptide is 
generated as unlabeled and stable isotope-labeled versions and characterized to assess the 
performance of the peptide assay in the digested matrix of interest and to enable 
quantification of the endogenous analyte via isotope dilution. Thus, the quality of peptides is 
a major determinant of reliable quantification. The specifications presented here are intended 
as a guide for procuring unlabeled and stable isotope-labeled peptides suitable for evaluation 
and analytical validation of targeted MS assays and to quantify peptides derived from 
proteins in proteolyzed biological fluids (e.g. serum/plasma, CSF, urine) and cell or tissue 
lysates. Specifications are provided for purified peptides and for “crude” or unpurified 
peptides.
Purified peptides are chromatographically purified after synthesis to remove most of the 
residual salts, synthesis reagents (e.g. deblocking and scavenger), partially deblocked 
peptides, and truncated peptides (29, 30). In addition, the amount of peptide and its purity 
need to be specified in advance to ensure that material of sufficient quantity and quality is 
available for assay development (see https://assays.cancer.gov/about/faq/ for guideline 
document for assay development and characterization). Purified peptides are typically 
analyzed by amino acid analysis (AAA) (31) to determine the net peptide content. Net 
peptide content is a measurement, usually in the form of a percentage that represents the 
amount of actual peptide within a gravimetrically measured sample. The measurement 
excludes the weight of water and counter ions that exist in all peptides. Crude peptides, on 
the other hand, may or may not be subjected to additional purification steps after synthesis 
(e.g., batch solid phase extraction) to remove synthesis by-products, and neither accurate 
quantity nor purity are possible. The identities of crude peptides must be confirmed by mass 
spectrometry, and since crude peptides vary greatly in purity it is recommended that further 
evaluation of purity (e.g., by reversed phase-HPLC-UV) or estimated quantity be performed 
by the end-user. While crude peptides can help confirm the identity of endogenous peptides 
and improve the precision of relative quantification within a research laboratory using a 
single batch of peptides, well characterized, purified peptide calibrators and detailed 
standard operating procedures are required to distribute assays to the community and 
harmonize results across laboratories. Importantly, methods intended for use in clinical 
laboratories use only the highest purity (isotopic and chemical) peptides available.
Unfortunately, the quality and consistency of peptides obtained from commercial sources 
vary widely. A large number of companies that advertise custom peptides for sale do not 
manufacture the peptides they sell, but are simply resellers of product made elsewhere. Not 
only will this have an effect on the batch-to-batch consistency of peptides over time (given 
the inability to trace production to specific laboratories), the instruments, resins, and amino 
acid building blocks, as well as the methods utilized to synthesize, purify, freeze dry and 
package peptides will vary widely dependent upon the manufacturer. It is recommended to 
use vendors that manufacture their own peptides, and that provide detailed specification and 
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characterization data for their synthesized products. For purified peptides, this must include 
MS data (preferably MS/MS data as well) and HPLC-UV chromatogram profiles, preferably 
using shallow gradients of no more than 2% change in organic concentration/min, otherwise 
the presence of impurities can be masked by co-elution of contaminant synthesis byproducts. 
More details on characterization are provided below. Regardless of whether the quality of 
the peptides is assessed by the vendor, a vendor sub-contractor, or in-house, the standard 
operating procedures used for quality control should be made available and linked to the 
corresponding quality control data.
High purity, well characterized peptides
To ensure that the quality of targeted MS data meets the specifications of the assay (e.g. 
specificity, precision, bias, lower limits of quantification), it is necessary to communicate 
with the peptide vendor and supply a comprehensive list of detailed specifications (e.g. 
chemical and isotopic purity, amount, formulation, aliquot size, packaging, etc.), as 
summarized in Table 2. Critical to the long-term success of assays that rely upon peptide 
calibrators and internal standards is working with a vendor(s) whose methods are well-
documented and whose personnel operate under SOPs to ensure consistency of production 
over time, and who are willing to customize their methods to meet the end-user's needs. 
Peptides can be ordered in any amount, from microgram to gram quantities. Peptide 
synthesis using current automated peptide synthesizers is typically performed at micromole 
scale (0.1 to 1 mmol) (32-34), which produces yields much higher than those required for 
targeted MS-based assays (∼ 10 fmol/peptide/sample or 100 picograms/peptide/sample for a 
peptide of MW = 1000 Da). Synthesizing peptides at larger scales results in higher yields, 
but increases the costs when stable isotope-labeled ‘heavy’ amino acids are used. We have 
found that a synthesis scale of 1 – 5 mg of purified peptide provides a reasonable balance 
between cost and yield. As shown in Table 2, one milligram is formulated for amino acid 
analysis (AAA; see below) and used in assay development. Additional quantities of 1 mg 
(up to 5 mg total), if ordered, can be delivered as dry powder and stably stored at -20 °C or 
below until needed.
Stable isotope-labeled amino acids used to produce stable isotope-labeled standard peptides 
can be synthesized with various elemental compositions (e.g., single position carbon, 
uniformly 13C labeling at all carbon atom positions, or combinations of 13C and 15N); see 
Table 2. While it is often less costly to use deuterium as the isotopic label, its use is not 
recommended because the presence of several deuterium atoms in a peptide can alter the 
peptide's retention time and prevent the desired co-elution with the unlabeled peptide 
(35-37). Further, deuterium atoms in reactive functional groups exchange with hydrogen 
atoms in aqueous solutions, which after time leads to the presence of unlabeled peptide in 
the internal standard. The difference in mass relative to the unlabeled peptide should be 
selected to be large enough to avoid interference of the natural peptide's isotopic envelope 
with that of the isotope-labeled internal standard, otherwise, inaccuracies in quantification 
can result (38). Peptide precursor m/z and charge state should be taken into consideration 
when selecting a mass difference for the heavy amino acid: the smaller the peptide and 
higher the charge-state, the larger the mass difference needs to be. For doubly charged 
precursors, a minimum separation of 6 Da is recommended, while 8-10 Da is recommended 
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for triply charged precursors. Lysine is available in isotope-labeled forms that are +6 and +8 
Da heavier than the unlabeled form, while arginine is available in +6, +8 and +10 Da 
versions. When additional internal standard peptides are going to be included to provide 
quality control for enrichment or other steps of sample preparation, additional labeled amino 
acids can be added to increase the mass difference.
The isotopic enrichment of the “heavy” amino acids used in synthesis should be greater than 
99% (Table 2). These percentages refer to the chance of finding the heavy isotope of an atom 
at each potential label site in the amino acid. Because more than one site in the amino acid is 
labeled (often 6-10 sites), the probability of finding a labeled atom at every labeled site is 
lower than the stated enrichment percentage (for a means to visualize this effect, see http://
www.chemcalc.org/main). Under-labeled peptide “isotopologues” will introduce 
inaccuracies in the quantification and can interfere with the measurement of the endogenous 
unlabeled peptide. For these reasons, it is advised to only use the highest possible isotopic 
purity labeled amino acids available (>99% enrichment per isotope) when having labeled 
peptides synthesized. It is also recommended that the relative ratio of heavy-to-light peptide 
be kept in a reasonable range < 1:25, and preferably <1:10. In clinical laboratories, the final 
concentration of internal standard peptide is most commonly set near a medically relevant 
concentration of the endogenous analyte. Other stable isotope-labeled amino acids can be 
used for incorporating in the sequence when K or R is not present in the peptide (protein C-
terminus).
During sample preparation, disulfide bonds in proteins are typically reduced, and cysteine 
residues are alkylated to prevent reformation of disulfide bonds with the aim of producing 
stable, denatured proteins with trypsin cleavage sites more accessible to the enzyme. When 
stable isotope-labeled internal standards are added post-digestion, cysteine residues in 
synthetic peptides need to be present in the identical alkylated form (e.g., 
carbamidomethylated, delta 57 amu). Synthesis of peptides containing chemical 
modifications such as phosphorylation or acetylation is now routine. However, it is worth 
noting that synthesis of multiply phosphorylated peptides have a higher failure rate than 
singly phosphorylated peptides. It should be noted that the production of recombinant 
proteins and peptides does not guarantee proper disulfide bond formation and this can 
impact digestion efficiency thereby causing the internal standard to behave differently from 
the native analyte in the assay.
The characterization of synthetic peptides during the course of synthesis and purification 
was described in the “Six Year Study of Peptide Synthesis” by the Association of 
Biomolecular Resource Facilities from 1991 -1996 (31). Reversed-phase HPLC (C18 
column) with UV monitoring is the best method to assess the complexity of peptide 
products, although examples of co-elution with truncated peptides have been observed (39). 
Mass spectrometry using either electrospray ionization (ESI) or matrix-assisted laser 
desorption ionization (MALDI) is essential for the identification of desired products and 
mass impurities. The coupling of RP-HPLC to ES tandem MS (LC-MS/MS) enables the 
confirmation of amino acid sequence and residue location of modifications (40). MALDI-
MS provides a means for identifying the molecular ion of the desired product and presence 
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of byproducts, although the relative ion intensities will not accurately measure the molar 
content of contaminants (41).
The purity and identity of purified peptides are typically evaluated using analytical reversed-
phase (RP) chromatography with UV detection (HPLC-UV; monitoring at wavelengths 214 
or 220 nm and 280 nm) and by mass spectrometry. The presence of multiple significant 
peaks in the HPLC-UV trace suggests the presence of synthesis side products; however, a 
single major peak may or may not correspond to the desired product. MS of the peaks in the 
UV trace (either by analysis of collected fractions using MALDI or, preferably, using on-line 
HPLC-MS) defines which peak is the desired peptide and which ones are impurities. 
MS/MS data are necessary to confirm the sequence of the desired product and to determine 
the chemical nature of impurities that may be present (e.g., incomplete deblocking, 
premature termination, etc.).
For characterization by HPLC-UV, MALDI, and especially amino acid analysis (AAA; see 
below) the peptide must be completely dissolved in solution. Importantly, the formulation 
and composition of the peptide used for quality control should be identical to that used for 
assay development and validation. The formulation range recommended in Table 2 was 
chosen based on our experience handling 1000's of tryptic peptides with a wide range of 
sequences, lengths and hydropathy profiles. We recommend formulating peptides in 5 – 
30 % acetonitrile with 0.1 % formic acid to a target concentration of 0.5-1 mg/mL 
(500-1000 μM) for AAA (see below) and evaluation by MS. The higher percentages of 
acetonitrile (up to 30%) are recommended for more hydrophobic peptides. Formulation and 
storage in neat DMSO is also possible, but oxidation of methionines may occur. Peptide 
solutions in DMSO need to be diluted prior to LC-MS analysis to avoid poor 
chromatography. It is also important to note that peptides stored in neat DMSO may 
precipitate when added to an aqueous solution, so use caution during dilution.
Crude (i.e., lower purity) peptides
Purification by preparative HPLC and quantification by AAA adds significantly to the cost 
of synthetic peptides. Eliminating these steps and generating “crude” peptides significantly 
reduces the cost for both natural abundance and stable isotope-labeled peptides. Due to this 
economy, a larger set of peptides can be selected and tested for development of a protein 
assay. Crude peptides (also referred to as partially purified peptides) are defined as the 
deblocked peptides that have been released from the solid phase resin and precipitated with 
an organic solvent (e.g. ether). Some vendors will perform an additional purification step. 
However, even after additional purification, preparations of lower purity “crude” peptides 
may still contain a wide range of impurities, such as residual salts, deblocking and scavenger 
reagents, and truncated and partially deblocked peptides.
The use of highly purified stable isotope-labeled internal standard peptides is recommended 
for the development of distributable assays and to improve between-laboratory agreement of 
assays that rely solely on peak area ratio for peptide concentration assignment. In addition, 
highly purified internal standards are vital for the successful development and deployment of 
clinical assays in a CLIA-regulated environment. However, crude peptides can be used for 
relative quantification of peptide analytes in Tier 2 assays (2), provided that the performance 
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of the resulting assay is carefully assessed. Crude stable isotope-labeled peptides can also be 
useful for identifying endogenous analyte, particularly in complex matrices such as cell and 
tumor digests. Figures of merit (e.g., LLOQ) of Tier 2 assays are often characterized by 
using various concentrations of unlabeled peptide calibrators in spike-in experiments. It is 
therefore important to remember that the use of lower purity peptides prevents accurate 
determination of assay LLOQ, hinders assay transferability, and complicates the 
comprehensive analysis of data and subsequent assay performance across research 
laboratories. Crude peptide preparations must still be analyzed by LC-MS/MS, and/or 
MALDI-TOF-MS to demonstrate that the correct sequence has been synthesized and that the 
desired product is the predominant species. Since purity varies considerably among different 
suppliers, crude peptides should also be analyzed by the laboratory developing peptide 
assays to ensure sufficient quality.
Table 3 summarizes the specifications and analyses to consider in qualifying crude peptides 
for assays that use a heavy-labeled peptide for each endogenous analyte (Tier 2) (2), or 
assays that use synthetic peptides that are not paired with each analyte (Tier 3) (2). The 
specifications differ from those of high purity peptides (Table 2) in the level of chemical 
purity and effort made to determine the exact quantity of peptide delivered. However, similar 
to high purity peptides, the isotopic purity should be specified to be > 99 % to obtain the 
highest sensitivity possible for measuring endogenous unlabeled peptide in the presence of 
the isotopically-labeled counterpart, as discussed above for high purity peptides. This can be 
assessed by using MALDI-TOF or LC-MS/MS of individual peptides or mixtures of 
peptides, respectively.
Figure 1 shows the MALDI-MS spectra of a high and lower purity peptide of the same 
amino acid sequence. These high purity and lower purity peptides were synthesized and 
provided from independent syntheses by the vendor using the specifications given in Tables 
2 and 3, respectively. A major signal that corresponded to the [M+1H]1+ ion (m/z = 
1854.94) for the FYGAEIVSALEYLHSR peptide was observed in both the lower purity 
(Panel A) and high purity (Panel B) peptide sample. The signal at m/z = 1570.68 is from a 
spiked internal mass calibration standard. In the case of the spectrum from the lower purity 
peptide preparation, there are multiple lower intensity peaks, likely byproducts of the 
peptide synthesis. For example, a peak consistent with the desired peptide minus the N-
terminal Phe residue (m/z = 1707.85) was observed (Fig. 1, Panel A).
Amino acid analysis of the high purity and lower purity peptide was performed to compare 
the amino acid content. Unlike the case for high purity peptides, the concentration of the 
desired peptide cannot be accurately quantified due to the presence of incompletely 
deblocked and truncated peptide species. Furthermore, in previous reports using AAA of 
crude peptide preparations to assess content without a desalting step were compromised by 
residual scavenger reagents (42). Table 4 compares the AAA of the high and lower purity 
peptides shown in Fig. 1. The molar content for the high purity peptide was in good 
agreement (within 10 %) with the expected molar content, particularly for the residues that 
are known to be most stable during acid hydrolysis conditions and those completely released 
during 24 h hydrolysis (Ala, Leu, and Phe). The presence of peptide species without the N-
terminal residue is consistent with the lower content of Phe in the lower purity preparation. 
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Some amino acids were not detected well in either the high or lower purity samples. 
Assuming complete residue deblocking and no interferences in the AAA from residual 
synthesis reagents, 274 nmol of peptide was measured using the averaged quantity from the 
fiducial residues, Ala and Leu. This value was lower than the amount of peptide quantity 
quoted for this lot of partially purified peptides by the vendor (i.e., 400 – 700 nmols/vial). 
Therefore, it is not possible to determine the lower limit of quantification of LC-MS/MS 
assays when crude peptides are used as standards. If employed in inter-laboratory studies, 
the same lot of the synthetic unpurified peptide dissolved into solution would need to be 
used.
Quantifying Pure Peptides by Amino Acid Analysis
Reliable quantification of purified peptides across synthesis batches and amongst vendors is 
critical to harmonizing concentrations of peptides determined solely from the endogenous 
peak area ratio with internal standard or determined with external peptide calibration 
materials across the community and over time. For biomolecule quantification, calibrators 
with accurate concentrations are frequently prepared by gravimetric methods [if analyte 
standards are available in sufficient quantity and of known purity (43)]. However, for 
peptides, preparation of calibrators with accurate concentrations using gravimetric 
preparation alone is often not feasible because of the limited available quantities and/or 
uncertain purity. In these cases, the concentrations of peptide calibration solutions can be 
determined through quantitative analysis of their constituent amino acids after hydrolysis of 
the peptide's amide bonds (44) (i.e., amino acid analysis; AAA). As mentioned above, AAA 
of pure peptide internal standards and calibrators is vital to the transferability of assays and 
aggregation of results amongst research laboratories. However, to improve the similarity of 
peptide concentration measurements, AAA of different batches of peptides must be accurate 
and precise, which fundamentally depends on the reliability of the methods, accurate 
calibration, and quality control of the AAA assays used to quantify amino acids in peptides. 
Clinical laboratories are much more likely to use purified proteins as internal standards and 
in external calibration materials. Proper quality control of the AAA assays used to assign the 
concentration of those proteins is equally important.
Vendors and service laboratories providing AAA analyses vary greatly in their processes and 
quality controls (QC). Further, peptide vendors offer different levels of assay quality (e.g., 
± 5-10 % CV, ± 10-25 % CV), therefore the accuracy of their AAA assays needs to be 
specified. Given the critical importance of AAA to the harmonization of peptide and protein 
concentrations over time within a laboratory and across laboratories, it is imperative to 
ensure that AAA determinations of assay internal standards and calibrators are performed 
with a high level of rigor. Before selecting an AAA service provider, it is strongly 
recommended to understand the workflow, standardization, and quality control measures 
that are in place. This critical information is summarized in Table 5 and discussed in more 
detail below.
Accurate peptide quantification by AAA does not require the measurement of all constituent 
amino acids; for most peptides, quantification can be achieved through measurement of one 
or more stable amino acids (see Figure 2 for a summary of amino acid characteristics). For 
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example, the most stable amino acids under the conditions of hydrolysis are Ala, Arg, Gly, 
His, Ile, Leu, Lys, Phe, Pro, and Val, whose side chains are not acid labile. These amino 
acids are arguably the best targets for quantification. Serendipitously, these amino acids are 
among the highest frequencies found in nature, and will be present in most peptides. There 
are some caveats to this list: (1) hydrophobic amino acids such as Ile, Leu and Val can be 
problematic due to their slow hydrolysis rate, (2) in the presence of phenol (e.g., 0.2%), Tyr 
is stable during acid hydrolysis and plays an important role in peptide quantification by UV 
spectroscopy, and (3) the basic amino acids Arg, His, and Lys have longer retention times on 
reversed phase-ion exchange HPLC columns compared with other amino acids. Under 
typical acid hydrolysis conditions, Trp is readily destroyed by oxidation. If the measurement 
of Trp is important, this hydrophobic amino acid can be instead hydrolyzed using 4 mol/L 
methanesulfonic acid containing 0.2 % (v/v) 3-(2-aminoethyl)indole for AAA quantification 
(45). Using only stable amino acids for quantitative AAA allows for the use of hydrolysis 
conditions which are optimized primarily for completeness of hydrolysis.
Prior to quantification of a peptide by AAA, there are preliminary considerations and 
experimental optimizations that should be addressed to achieve accuracy. First, the purity of 
the peptide should be evaluated (46). Specifically, it should be determined whether the 
peptide contains any impurities that could contribute to amino acids, biasing the quantitative 
AAA. Errors during peptide synthesis and degradation products of the peptide are potential 
impurities. An LC-MS/MS analysis of the peptide should be performed to determine if 
peptide impurities are present and to provide a rough estimate of their amounts relative to 
the analyte peptide. If relative content of peptide impurities are high, a purification of the 
analyte peptide should be performed prior to AAA.
It is important to verify that peptides are completely dissolved prior to AAA to ensure that 
the measured concentrations of peptide in solution are relevant to the lyophilized peptide 
stock. Further, it is important that the protocol for solubilization of peptides prior to AAA is 
identical to the protocol used to solubilize the peptide internal standards and calibrators prior 
to use in the quantitative assay. Best practice would use UV-spectroscopy to confirm 
calibrator solution concentration prior to use.
AAA assays should be considered as three key steps (discussed below) with an optional 
derivatization stage commonly employed either pre- or post-column for increased signal 
response. In general, AAA assays include: 1) peptide hydrolysis, 2) separation of amino 
acids, and 3) detection with quantitative analysis.
Peptides are commonly hydrolyzed at elevated temperatures (110° C, but can range from 90 
to 130° C) in a low pH environment using concentrated acids (6 mol/L HCl, 4 mol/L 
CH3SO3H, 2 mol/L TFA, etc.). Alkaline hydrolyses are also possible using concentrated 
KOH or NaOH, although this approach is not as commonplace. Acid hydrolysis can be 
performed in two ways: in concentrated acid solution or with acid in the gas-phase. Elevated 
temperatures used for hydrolysis are obtained using a conventional oven, heating block 
approach, or in a specifically designed microwave oven to control energy and temperature.
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Separation of amino acids prior to detection can be achieved by several formats, including 
HPLC [ion-exchange (IEX) and reversed phase (RP)], gas chromatography, or 
electrophoresis. RP-HPLC and GC typically require chemical derivatization prior to 
detection, although newer HPLC column chemistries are facilitating improved retention 
characteristics and enable baseline separations of non-derivatized amino acids, limiting 
biases and imprecision associated with a derivatization step (47). High resolution amino acid 
separations are also possible using capillary electrophoresis (48).
Detection of amino acids is most commonly performed using one of several types of 
detectors: 1) a spectroscopic detector as used for Vis/UV or fluorescence, 2) measurement of 
electric current from redox reactions using amperometric electrochemical detection, or 3) 
mass spectrometry. Spectroscopic and electrochemical detections offer higher sensitivity, 
while mass spectrometry offers better selectivity in complex matrices and the capability of 
isotope-dilution quantification techniques. Non-chromatographic MS-based methods for 
amino acid analysis have also been developed (49).
The National Institute of Standards and Technology (NIST) has developed a AAA method 
based on isotope dilution (ID) LC-MS/MS analysis, which uses a stable isotope-labeled 
analog of each amino acid measurand that is spiked both into samples and calibrants in an 
equivalent manner. This “double isotope dilution” technique is beyond what routine 
laboratories would normally use, but is routinely used at NIST to certify concentrations for a 
wide variety of analytes (50). Amino acid calibration solutions are prepared gravimetrically 
from reference materials spiked with 13C- and 15N-labeled amino acids. The amino acids 
used in the calibration solutions are rigorously characterized for purity using elemental 
analysis, Karl Fischer analysis (for water content), NMR, and HPLC-UV. Calibration curves 
are generated from experimental peak area ratios and gravimetric mass ratios for unlabeled/
labeled amino acid pairs. Internal standards used for quantification are spiked into the 
samples prior to hydrolysis to limit biases associated with the sample preparation. For 
accurate quantification, exact-matched internal standards are individually diluted and added 
at concentrations that more closely match the concentrations of each amino acid in the 
sample, and the quantification is repeated. This AAA method has been used to measure total 
(purified) protein concentrations or concentrations of free, unbound amino acids (51) in 
several NIST Standard Reference Materials (SRM®) (http://www.nist.gov/srm). Peptide or 
protein concentration is determined independently for each target amino acid and then the 
concentrations from each amino acid are compared to assess measurement quality. 
Measurement uncertainties of peptide or protein concentrations are calculated based on this 
propagated error and expanded uncertainties are determined through advanced statistical 
analysis. Typical coefficients of variation for AAA measurements using the NIST method 
are within 3 %.
The NIST double isotope dilution LC-MS/MS method for AAA is intended to value-assign 
peptide and protein reference materials(51) with high accuracy and low uncertainty. For 
routine AAA, this approach may be unnecessarily labor-intensive and time-consuming, and 
the added cost could factor into the cost of the production of large numbers of peptides. As 
an example of the way routine AAA assays are simplified, norleucine is often used as the 
internal standard at a single concentration because it is relatively inexpensive and easier to 
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use than multiple exact-matched, isotopically-labeled amino acids, it is chromatographically 
resolved from other measurands, and it is stable under acid hydrolysis. Although less 
complicated measurements are possible, adequate quality control steps, such as those 
described below, are needed to achieve the required measurement goals.
The peptide hydrolysis and amino acid quantification steps are most challenging during 
AAA, and, therefore, the most prone to bias. As such, quality control efforts in routine AAA 
should focus on these steps. The completeness of hydrolysis can be impacted by the amino 
acid sequence of the peptide, as neighboring effects of adjacent amino acid side chains alter 
the efficiency of the hydrolysis reaction. Therefore, both the time and temperature needed to 
achieve complete hydrolysis could be peptide-specific. To achieve the highest accuracy in 
peptide quantification, the AAA hydrolysis time and temperature should be optimized for 
each peptide (amino acid) using a timecourse assessment of amino acid stability and 
completeness of hydrolysis. A comparison of the peptide concentrations derived from each 
amino acid monitored can be a useful way to identify problems with hydrolysis 
completeness. If statistically equivalent peptide concentrations are not observed for all the 
stable amino acids measured, it is likely that either peptide hydrolysis was not complete, 
there are unknown, significant impurities remaining, or there is a problem with the 
quantitative amino acid measurement.
For the hydrolysis step, a peptide solution with a known concentration should be used as a 
trueness control. In the absence of an appropriate peptide solution reference material, labs 
performing AAA should consider preparing an in-house peptide standard. An appropriate in-
house peptide solution standard can be prepared from a high-purity peptide and be value-
assigned using a double isotope dilution LC-MS/MS method. Sufficient aliquots of the in-
house peptide standard should be prepared and stored frozen so that an aliquot will be 
measured as a trueness control with every routine AAA measurement. A discrepancy from 
the expected peptide concentration of the in-house standard during routine AAA analysis 
could indicate either a problem with peptide hydrolysis or with accuracy of amino acids 
measurement, or both. It would be possible to rule out problems with amino acid 
measurement by using an amino acid solution reference material of known concentration, 
such as NIST SRM 2389a (52). Through the combined use of a peptide and amino acid 
standards, sufficient accuracy in routine AAA can be achieved.
Amino acid calibrants and peptide/protein QC materials should be selected carefully to 
ensure accuracy of the measurements. Calibrants should mimic the measurand(s) as 
identically as possible in both concentration and structure/form. Calibrants should be 
characterized for purity, both organic and inorganic contaminants, as well as for water 
content. Both calibrants and QC materials should be measured in a buffer that most closely 
resembles that of the target measurand. Similarly, QC materials should ideally consist of 
pure proteins or peptides with known, accurate, and stable concentrations; the calibrators 
and QC material should be well characterized with respect to purity, storage stability and 
accuracy of the aliquot. Because AAA of peptides is limited by which amino acids are 
available for targeted quantification, it is necessary to ensure that the QC material contains 
the same set of amino acids in roughly (if not identically) the same molar ratio. For isotope-
dilution measurements, stable isotope-labeled internal standards must consist of matrix- and 
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exact-matched analogs of the target measurand. They should be added to the samples and 
calibrants at the beginning of the sample preparation; accuracy of the amount of the sample 
taken for the analysis must be assured, and replicate analysis of the measurand is preferred. 
To ensure coelution of the targets with the corresponding internal standards during 
chromatographic separation, deuterated internal standards should be avoided (53). Finally, 
labeled amino acid internal standards should contain a number of isotopic atoms which 
would provide sufficient mass difference from the isotopic envelope of their “light” analogs 
in order to be detectable without bias contingent on the resolution of the chosen mass 
spectrometer.
Need for reference materials for harmonization of AAA measurements
To help facilitate accurate and precise AAA measurements by service providers, the field 
would greatly benefit from a new set of reference materials for harmonization. Ideally, the 
new standard peptide(s) would lack specific amino acids that are degraded during hydrolysis 
(Trp, Met, Cys, Ser, and Thr), lack amino acids that have limited stability during long-term 
storage (Trp, Met, Cys, Asn, and Gln), and lack amino acid pairs that often don't hydrolyze 
completely (e.g., Ile-Val, Ile-Ile, and Val-Val). Including a tyrosine in the peptide would 
allow UV-absorption to be used to quantify the peptide using alternative methodology (UV-
absorption) and including at least one of the most reliable amino acids (sometimes called 
fiducial residues) ensures greater confidence in the final results [i.e., Tyr (with phenol 
present), Ala, Arg, Gly, His, Ile, Leu, Lys, Phe, Pro, and Val]. The optimal peptide length to 
minimize secondary structure and ensure complete hydrolysis is 12-18 residues.
Whether standard peptides are provided in solution or as lyophilized peptides, the peptides 
would ideally be stable in solution for at least 30 days at 4 °C and for 3 years at -20 °C. 
Peptides in solution should also be stable to multiple freeze-thaw cycles and to at least one 
lyophilization-resolubilization step (in aqueous/organic/acid solvent) without significant loss 
of peptide (i.e., < 3 %) or modification of residues. While it is not possible to know how 
soluble and stable a peptide will be prior to synthesis, an example peptide that might be a 
useful standard peptide for AAA is DAKAGIHPLELRVARYR. This artificial, non-tryptic 
peptide that is not present in any gene sequence is 17 residues in length, 15 of its residues 
are taken from the list of most reliable amino acids, it contains at least half of the natural 
amino acids including Tyr, it lacks unstable side chains and amino acid pairs that hydrolyze 
irreproducibly, and it is relatively charge balanced (2 acidic and 5 basic residues) making it 
readily soluble for use in other assays.
Although it is not possible to produce reference materials suitable for every potential peptide 
application, availability of general reference materials will have a large impact on quality of 
the measurements. Due to the issues associated with using weighed amounts of peptide (e.g., 
salt and water content of lyophilized peptides), it is very desirable for the field to have 
available one or more standard peptides already in solution, ready for use in amino acid 
analysis. For example, the NIST peptide standards SRM® 8327, which were provided as a 
reference material without a certified concentration measurement, were aliquotted 
gravimetrically (target of 1 mg of peptide per vial) and then distributed as lyophilized 
peptides. The data in Table 6 demonstrate that the actual amount of peptide added to the vial 
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was much lower than 1 mg for each peptide (determined using amino acid analysis), due to 
salts and water associated with the lyophilized peptide.
In summary, the field of proteomics would greatly benefit from new reference materials 
developed and carefully characterized using a double isotope dilution technique. The new 
reference materials would include 1 to 3 peptides in solution that are soluble, stable, contain 
the most reliable amino acids for AAA, and be representative of the proteotypic peptides 
that are used in targeted proteomics experiments. Service providers would use these 
reference materials to ensure the accuracy of their assay during the methods development 
and in routine use of the methods.
Peptide storage and handling
Quantitative mass spectrometry-based assays are negatively impacted by a lack of proper 
procedures for storing and handling peptides. The following section highlights several of the 
most common considerations and makes recommendations for storing and handling peptide 
internal standards and calibrators (for a summary of the general recommendations see Table 
7).
Peptide Storage
The primary detriments of extended storage of peptides are the loss of solubility and/or 
change in concentration due to evaporation, adsorption, microbial degradation, secondary 
structure formation, and chemical modification. Storage in buffers can render peptides 
susceptible to microbial growth and degradation. Specific amino acids are associated with 
several common chemical modifications. For example, cysteine, methionine, and tryptophan 
are prone to reversible and irreversible oxidation, and this conversion is accelerated during 
freeze-thaw cycles and at high pH (54). Glutamine and asparagine are prone to deamidation 
(55), frequently when drying solutions under acidic conditions. Certain positions are more 
susceptible to deamidation, including the N-terminus and N-terminal to glycine (i.e. Asn-
Gly, Gln-Gly). Aspartic acid is sensitive to hydrolysis, and amino acids containing aromatic 
rings are susceptible to photochemical degradation (e.g., phenylalanine and tryptophan).
To minimize detrimental effects, the long-term storage of peptides (> 6 months) is most 
effective when peptides are lyophilized and stored at temperatures -20 to -80 °C (33, 56). 
Upon reconstitution, the primary concern is variability in the dissolution of peptides. 
Generally, AAA constitutes the best practice for concentration determination; however, for 
peptides with well-characterized solubility, UV absorbance using pre-defined extinction 
coefficients may be a suitable alternative. Once re-solubilized, the peptide calibrator 
solutions (0.5-2 nmol/μL) are best stored frozen at temperatures ≤ -70 °C in sealed tubes. 
Although stability in solution is peptide-dependent, generally working solutions are prepared 
from the stocks at concentrations 1-100 pmol/μL and are used for short term storage of 
peptide calibrators (≤ 3 months). To minimize peptide degradation, multiple freeze-thaw 
cycles should be avoided. Using good laboratory practice (preferably using gravimetric 
addition), calibrators should be made from the stock solution diluted as close to the time of 
use as possible. Peptides in solution should also be limited in their exposure to air. For 
particularly sensitive sequences, inert gases (e.g. argon, nitrogen) are recommended as a 
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blanket gas in storage tubes, and amber or dark storage tubes should be used for 
photochemically sensitive sequences.
Reconstituting Peptides
As mentioned above, solubility can be a significant factor affecting the accuracy of peptide 
quantification. Peptide solubility in a given solvent depends greatly on the specific amino 
acids in the peptide. The diversity of peptide sequences makes it difficult to apply broad 
recommendations to optimize solubility; however, general guidelines can be followed. 
Acidic peptides that contain more Asp and Glu residues than His, Lys and Arg residues are 
most soluble in basic solutions. Basic peptides containing more His, Lys and Arg residues 
than Asp and Glu residues are most soluble in acidic solutions. Peptides with neutral or < 
25 % charged residues are most soluble in solutions to which an organic solvent has been 
added. Solutions with strong organic solvents such as acetonitrile or DMF 
(dimethylformamide) can be used to efficiently solubilize peptides with a high percentage of 
hydrophobic residues (> 50% Ala, Val, Leu, Ile, Met, Phe, Trp, Pro) and < 25 % charged 
residues.
Prior to reconstituting peptides, lyophilized powder should be brought to room temperature 
in a desiccator to avoid water absorption in the unused peptide, thus minimizing variations in 
concentration of lyophilized aliquots. If reconstituting a peptide for the first time, and 
whenever possible, a small amount of the peptide should be reconstituted before committing 
the entire lot by weighing out a small aliquot. As discussed above, the pH is an important 
parameter for peptide solubilization. Initial reconstitution is best performed in water by 
adjusting the pH based upon the primary amino acid sequence with a small amount of 
organic solvent added to aid solubilization. Buffers such as PBS should not be used for 
reconstitution because salts hinder solubility. If salt solutions are desired for the final 
formulation, they are best added once the peptides are fully solubilized.
Peptides should initially be reconstituted at a concentration that is higher than the desired 
final working concentration (typically between 10-1000 times more concentrated; see Table 
7 for specific recommendations). Solutions of completely solubilized peptides are 
completely clear and are devoid of any “flecks” or cloudiness. Solubilization can be 
confirmed by light scattering analysis or by comparing absorbance in a series of dilutions 
with and without centrifugation to pellet undissolved material. A general recommended 
starting point for a reconstitution solution is 5 % acetonitrile with 0.1-1 % formic acid. The 
inclusion of organic solvent and acid in the reconstitution solution not only aids solubility, 
but also serves to retard microbial growth (biologically active buffers should contain 0.1 % 
sodium azide to prevent microbial growth). If this reconstitution solution is not successful in 
completely solubilizing the peptide, the amount of organic solvent can be increased or the 
organic solvent can be altered (e.g., try methanol instead of acetonitrile). If increasing 
organic solvent is not effective in solubilizing the peptide, the pH can be adjusted by adding 
acid (up to 1 % formic acid or TFA), or by using 1 % ammonium bicarbonate, 1% DIPEA 
(N,N-diisopropylethylamine), or ammonium hydroxide. Another option is to re-dry the 
peptide and re-dissolve it in DMSO.
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Non-specific Adsorption of Peptides
Variable recovery due to non-specific adsorption is one of the major consequences of 
improper handling of peptides and can lead to imprecision and bias (i.e., loss of peptide to 
surfaces or contamination/carryover). The extent of non-specific peptide adsorption to the 
walls of peptide storage vessels, pipette tips, autosampler vials, and HPLC components 
varies based on the primary sequence, the materials used, and the concentration of the 
peptide solution. Complete characterization of peptide stability includes the evaluation of 
losses due to adsorption in all steps of the analytical method. This can be accomplished by 
several experimental designs, including measuring peptide amounts in serial dilutions by UV 
absorbance (e.g. to evaluate potential loss in tubes and/or pipet tips) or repeated injections 
by LC-MS (e.g. to evaluate potential loss or carryover in vials and the HPLC system). The 
use of carrier or chaperone molecules can minimize adsorption effects for particularly 
difficult peptides (57); however, choice of a suitable carrier is highly dependent on the 
peptide sequence, the analytical method, and the desired matrix for analysis. Thus, there is 
currently no consensus related to the best carrier molecules or the optimum concentration for 
use with peptide internal standard and calibrators. When evaluating carrier molecules, 
caution should be taken to choose components that do not interfere with detection of the 
target peptide or excessively contribute to sample complexity or instrument contamination.
The relative loss of peptides by non-specific adsorption in low concentration solutions is 
greater than in more concentrated solutions because of the limited binding capacity of the 
wetted solid surface area (58). To demonstrate the loss of peptides in solution and the effect 
of storage concentration, two peptide mixtures (200 and 1000 fmol/μL) were prepared in 
non-deactivated glass vials and analyzed by injecting 1 μL of each sample each h for 15 h. 
Of the 50 peptide targets in each mixture, 48 and 50 peptides were detected in the 200 and 
1000 fmol/μL samples, respectively. Nine and zero peptides, respectively, showed noticeable 
signal decay over time under the above two conditions. This effect is seen by plotting total 
peak areas of two representative peptide sequences: YLGYLEQLLR (SSRC Relative 
Hydrophobicity 41.55) and IYEGSILEVDCDILIPAASEK (SSRC Relative Hydrophobicity 
43.98), both of which are quite hydrophobic (Figure 3). In contrast to the 200 fmol/μL 
sample, all peptides in the 1000 fmol/μL mixture showed constant signals over the time 
period analyzed, consistent with improved stability and reduced adsorption at higher 
concentration.
Non-specific adsorption contributes to carryover, which increases variability and bias due to 
residual signal in sample runs (59). Carryover in sample preparation can originate from re-
using pipette tips to transfer peptide solutions between vials or in dispensing aliquots. 
Carryover in sample preparation or analysis can negatively impact results through ion 
suppression of low abundance peptides (when co-elution occurs with high abundance 
carryover from the previous run or sample) or by producing a ‘false positive’ in sample 
analysis by the detection of contaminating analyte peptide. One can determine the extent of 
non-specific adsorption by transferring a solution of the analyte sequentially from one vial to 
another and analyzing a small aliquot after each transfer step to assess for losses (60). 
Despite the diverse physicochemical properties of peptides, various strategies can be 
generically applied to reduce adsorption and cross-contamination phenomena (57, 61) 
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leading to carryover. When preparing dilution series, one should never re-use pipette tips to 
avoid cross-contamination. Pipette tips should be pre-rinsed several times with the peptide 
solution prior to aspirating the final volume. To minimize non-specific adsorption to the 
walls of storage vessels, standards of peptides should be added directly to the diluent fluid 
instead of the sides of the tubes or vials. Finally, peptide adsorption also contributes to 
carryover in chromatographic systems through incomplete removal of analyte from the 
analytical system from the previous injection (e.g. insufficient wash of the injection valve or 
syringe of the autosampler). Chromatographic carryover can be evaluated by injecting a 
blank sample following a sample or calibrator. Complete system wash runs (e.g. rinsing all 
HPLC components, including autosampler, delay volumes, and columns) can be used to 
reduce or eliminate carryover using a series of different elution buffers/solvents. It should be 
noted that some peptides, especially those containing hydrophobic residues, can be retained 
on HPLC columns despite the use of high concentrations of organic solvents when washing. 
Most HPLC column manufacturers have published methods for washing/cleaning the HPLC 
flow-path and columns.
Different types of vials can introduce significant variability in LC-MS analyses (62). The 
interaction of peptides with various surfaces is greatly influenced by the specific side chains 
of the amino acids of the peptide. Glass and polypropylene are the materials that are most 
commonly used to manufacture vials, inserts, and plates. Although a single type of vial 
might not be optimal in terms of minimizing the non-specific interaction of all of the 
peptides in an analytical mixture, it should be noted that basic amino acids can form 
electrostatic interactions with the residual silanol groups on glass vials, and nonpolar amino 
acids can interact with the hydrophobic surface of polypropylene vials (63). To minimize 
these adverse interactions, several manufacturers of chromatography consumables offer 
silanized glass vials in which the silanol groups have been chemically inactivated. Similarly, 
polypropylene vials with modified plastic surfaces are commercially available.
To demonstrate the variability that can arise from various container materials, we 
investigated the signal from repeated injections of a digested protein sample stored in three 
types of autosampler sample vials: non-deactivated glass, deactivated glass, and 
polypropylene vials. Peptide stability was tested by performing 15 repeated LC-MS/MS 
analyses of the 50 fmol/μL sample each h for 15 h. We manually assessed the signal 
intensities of the replicate runs for each peptide to determine the amount of signal 
enhancement or decay. The results are summarized in Figure 4. Peptides were categorized as 
Stable, Slow decay, or Fast decay by using a cut-off of < 5%, 5-50%, or > 50% peptide loss 
based on signal intensity over the 15 h. We found that all three vial types enable the recovery 
of 43 peptides, which accounts for 86% of the monitored peptides. Twenty-nine of the 
detected peptides were very stable across all analyses for all vials. In this study, the 
polypropylene vial outperformed the two glass vials, as only 1 “unstable” peptide with 
significantly lower recovery was detected, while 13 and 14 “unstable” peptides were 
detected in non-deactivated and deactivated glass vials, respectively.
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Effects of Freeze-thaw on Peptide Stability
To demonstrate the effects of freeze-thaw on peptide stability, we compared the signal 
intensity observed when injecting a peptide mixture stored at 4 °C, a sample undergoing a 
single freeze-thaw, and a sample undergoing multiple (n=10) freeze-thaw cycles. Twelve 1 
pmol/μL sample aliquots prepared in solution (3% acetonitrile, 0.1% formic acid, in H2O) 
were stored in polypropylene tubes at -80 °C. One sample was thawed and kept at 4 °C over 
10 days, and one sample was subjected to 10 freeze-thaw cycles. The remaining ten samples 
underwent a single freeze/thaw. Each sample was analyzed in triplicate by LC-MS/MS by 
injecting 50 fmol on column (diluted from the stock solution immediately prior to the 
analysis) from each sample over ten consecutive days. The results are summarized in Figure 
5. Figure 5A shows the mean total peak areas of all detected peptides over 10 days. Because 
there is a wide distribution of the peptide MRM intensities, three plots were made to show 
peptides with low signal abundance (peptides with poor ionization), medium signal 
abundance (middle box), and high signal abundance, respectively. Regardless of how the 
samples were handled, comparable peak areas of the peptide were observed (Figure 5A), and 
there was no significant difference (paired t-test, p<0.05) among the average peak areas for 
the freeze-thaw experimental conditions.
We next assessed the reproducibility under the three conditions by comparing imprecision of 
the replicate analyses (Figure 5B) and found a number of important observations: 1) the 
variability of peptide peak area (%CV) is sequence-dependent and closely related to the 
peptides' hydrophobicity, 2) no obvious correlation was observed between peptide peak area 
and variability (within the limits tested), 3) for most peptides, variability of peptide peak 
area (%CV) was lower for freezer storage (∼1.5-3.5 fold) than for other storage conditions, 
and 4) the variability of peptide peak area (%CV) was highest after ten freeze-thaw cycles. 
These results clearly suggest that frequent freeze-thaw cycles should be minimized, and best 
results are obtained from analysis of samples that are stored frozen and defrosted 
immediately prior to the analysis.
Peptide Storage in the Autosampler
After peptide calibrators have been properly prepared and added to the most appropriate 
type of vial, the amount of time that the peptide calibrators are stored in the autosampler 
must be carefully controlled. Ideally, stability studies should be conducted to determine 
whether peptide calibrators can be prepared and left in an autosampler with thermostatic 
temperature control for the duration of the analysis without decreased mass spectrometer 
signal. Peptides should be conditioned to the autosampler tray temperature prior to injection. 
Temperature-related differences in peak area have been observed when peptides were not 
equilibrated to the autosampler tray temperature before injection (64). Further detailed 
guidelines for conducting a study to determine the stability of peptides are provided in the 
Assay Development Guidelines document that is available on the CPTAC Assay Portal (4) 
(https://assays.cancer.gov/) and published recommendations (11). Briefly, the guidelines 
recommend the analysis of peptide peak area variability for six temperature- and time-
related conditions (6 h at 4 °C, 24 h at 4 °C, 4 weeks at -70 °C, one freeze-thaw, and two 
freeze-thaws) compared to the time zero condition wherein the peptides are injected directly 
without being left on the autosampler tray for a prolonged period of time.
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In summary, the best storage and handling conditions will depend on peptide sequence. 
However, despite the individuality of peptide sequences, some general recommendations for 
peptide handling can be made (summarized in Table 7).
Assuring specificity and reliability of quantitative data based on peptide 
internal standards and calibrators
When analyzing the data from LC-MS/MS assays of peptides and proteins, it is critical to 
confirm the specificity of the assay for the intended analyte, as well as to ensure reliable 
quantification of the analyte. The use of the stable isotope-labeled internal standard peptides 
facilitates both of these goals, as described below.
Well developed and validated targeted LC-MS/MS assays are able to provide highly specific 
measurements, since the actual peptide analyte (i.e. not an indirect measurement of the 
analyte, such as a chromogenic or chemiluminescent substrate used with most 
immunoassays) is directly detected by the mass spectrometer, and every peptide has 
characteristic physiochemical properties (e.g., HPLC elution time, precursor and product ion 
masses, and product ion ratios). Nonetheless, interferences are common in highly complex 
biological matrices, and they must be recognized and avoided to ensure assay specificity. For 
example, in complex matrices (e.g., plasma, serum, cell or tissue lysates) combinations of 
several precursor/product ion pairs (i.e., “transitions”) are often insufficient to accurately 
pinpoint the location of a given target peptide (especially for low-abundance analytes). This 
is because multiple “peak groups” (i.e., “clusters” of co-eluting or closely eluting 
chromatographic peaks in the retention time window of each measured transition) are likely 
to be present. However, with the use of internal standards, the endogenous peptide signals 
can be easily located in the HPLC elution profile, because the stable isotope-labeled peptides 
and their endogenous counterparts have very similar fragmentation patterns and HPLC 
retention times. The LC-MS peak characteristics of the light and stable isotope-labeled 
peptides can be manually inspected using Skyline (15) or analyzed using automated data 
processing (e.g., peak picking, quantification and false discovery rate calculation) with 
software tools such as mProphet (65). Observing the same fragmentation patterns [i.e., the 
same transition and the same relative peak intensity ratios across multiple transitions(66)] 
between the endogenous and stable isotope-labeled peptide signal patterns is used to 
qualitatively confirm confident detection of the endogenous peptide, as well as to determine 
potential interferences in specific transition(s) either by manual inspection or using the 
software tool AuDIT (67). In general, if ≥ 3 transition ion pairs (heavy and light) for a given 
peptide show identical LC elution time profiles and the relative intensity of the product ions 
is within the tolerance established during the assay validation, the assay can be considered to 
be specific.
To achieve reliable relative quantification of peptides in complex matrices, the targeted 
proteomic assay must be analytically characterized with respect to its specificity, LLOQ, 
linear range, precision, and repeatability. Guidelines for targeted proteomic assay 
characterization have been proposed (2, 11) and a summary document can be downloaded 
from the CPTAC assay portal (https://assays.cancer.gov/)(4). Open source software tools 
(15, 68) are available to facilitate analyses and data sharing. Validation of quantitative assays 
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of proteins in complex mixtures requires additional experiments (11) and analytical 
validation in a clinical laboratory should adhere to appropriate guidelines (i.e., Clinical 
Laboratory Standards Institute and CLIA).
It is generally recommended that the most intense ion that is free of interference be used to 
quantify the peptide, and that the next two most abundant fragment ions are monitored to 
evaluate specificity of the assay. It is also acceptable to sum transitions for quantification if 
there is a signal-to-noise benefit (and if all these transitions are demonstrated to be free of 
interference in each sample tested). If the target peptide contains a specific post-translational 
modification, then there must be at least one fragment containing the modified residue (69). 
In PRM experiments, all product ions are detected and could be quantified simultaneously, 
with a subset of those product ions used to evaluate selectivity. A summary of the 
recommended steps for analyzing targeted quantification results using isotopically-labeled 
peptide internal standards is presented below:
1. Check the extracted peaks for both heavy standard and endogenous light peptides 
using software tools such as Skyline (15), making sure that both peaks co-elute.
2. Confirm the transition pattern (rank and relative intensity, typically requiring at 
least 3 transitions) is consistent between the isotope-labeled internal standard and 
endogenous peptide. The confidence of detection of endogenous peptide is assured 
by comparison of the acquired transitions between the isotope-labeled internal 
standard and endogenous peptide.
3. Eliminate transitions with potential interference. The problematic transition could 
be determined either by visual inspection or software tools such as AuDIT (67).
4. Select the appropriate peak boundary for the labeled and endogenous peptides, and 
then calculate their peak areas. Either all transitions or the best transition (i.e., 
highest intensity, lowest limit of quantification, or best signal-to-noise) without 
evidence of interference can be used for quantification.
5. Calculate the peak area ratio of endogenous peptide over stable isotope-labeled 
peptide. Based on the peak area ratio and the known concentration of the spiked 
stable isotope-labeled peptide, the concentration of endogenous peptide in the 
unknown sample can be determined.
6. Ensure that the detected concentration of the peptide is above the LOQ of the assay 
and within the linear range of the assay.
As mentioned above, there are several reasons why this approach may not accurately reflect 
the amount of endogenous peptide or protein present in the undigested sample: (1) liberated 
peptides are lost or non-specifically degraded during digestion, especially with high 
concentrations of trypsin and long digestion times (70), (2) proteins in complex mixtures are 
often not digested to completion when trypsin is added in lower concentrations, (3) proteins 
are most often heterogeneous mixtures of related macromolecules that differ in primary 
sequence and post-translational modifications, which can affect digestion efficiency, (4) 
proteins in macromolecular complexes that are not completely denatured will digest less 
efficiently, and (5) there is substantial variability in digestion from day-to-day. Even if 
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inaccurate, the quantification of peptides in LC-MS/MS experiments can be relatively 
precise from day-to-day when the peak area ratio is calibrated using external calibration 
materials. These materials can include unlabeled or labeled peptides spiked into a relevant 
digest (e.g., pooled cell lysates or human serum) at various concentrations, which are 
prepared in parallel with other samples (i.e., internal standard is added at the same 
concentration). This minimizes bias due to variable amounts of internal standard added each 
day. Alternatively, purified protein spiked into a relevant matrix or native protein present in 
an unadulterated sample can be used. This approach can normalize between-day and 
between-laboratory variability in digestion (5-7, 71), but it must be realized that the 
measurement may still not accurately reflect the amount of intact protein in the sample.
Reference materials: Improving the harmonization of protein measurements
To avoid pitfalls in interpreting targeted LC-MS/MS peptide and protein measurements, it is 
critical to properly identify the measurand (i.e., the quantity intending to be measured). For 
the most part, this document has focused mainly on the approaches and techniques needed to 
effectively utilize stable isotope-labeled internal standard peptides in the quantification of an 
endogenous peptide in a proteolytic digest of a complex sample. In most instances, the goal 
of MRM assays is to measure the concentration of a target protein in a complex mixture. As 
discussed above, the concentration of a proteotypic peptide liberated in a protein digest may 
not fully reflect the concentration of an intact protein, particularly due to the heterogeneity 
of protein isoforms in biology. However, if the measurand is defined as the concentration of 
protein isoforms that contain the peptide(s) analyzed in the experiment, then with proper 
calibration and quality control, LC-MS/MS may be capable of providing this concentration.
Reference materials can be used to harmonize and standardize measurements of protein 
measurands. For quantitative methods in clinical laboratories, the accurate measurement of 
proteins is important for patient care, particularly when accurate diagnosis, treatment 
guidelines, or prognosis are based on the numeric results of laboratory tests. Relative 
accuracy in these assays is established using reference materials whenever possible (72, 73). 
The reference materials are used as calibrators in the assay or to assign the concentration of 
a protein in the assay calibrators, regardless of whether the assays are immunoassays or 
mass spectrometric assays. Assays that demonstrate good agreement on a population of 
samples are said to be harmonized. Reference materials can be used to harmonize assays. 
When an assay reports concentrations on a population of samples that have very little bias 
when compared with a reference measurement procedure (i.e., a robust assay with rigorous 
process controls that uses certified or standard reference materials in its calibration), the 
assay is said to be standardized. It is possible to harmonize and standardize immunoassays 
or mass spectrometric assays (74).
Standard or certified reference materials have had their concentration assigned by consensus 
or reference measurement procedure. Consensus-defined concentrations use as many 
different assay platforms as possible (typically immunoassays) to assign the concentration. 
Consensus-defined reference materials are useful for the harmonization of protein 
measurements. Reference materials that use a reference measurement procedure to define 
their concentration are rare. For purified protein reference materials, the measurement 
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procedure of choice is currently amino acid analysis. For proteins in a relevant matrix, there 
are no reference measurement procedures that use tandem mass spectrometry to assign 
protein concentration. The most commonly used methodology is immunoassays using 
polyclonal antibodies, which have well-known issues in analysis of human biological fluids 
(75). In these cases the measurand is difficult to define with any specificity.
Guidelines have been developed by the International Organization for Standardization (ISO 
15194), which ensure the quality of manufactured reference materials. The World Health 
Organization (WHO) has developed complimentary guidelines for the development and 
value assignment of their international standards. Table 9 lists possible sources and 
distributors of protein reference materials that may be useful to investigators and clinical 
laboratories.
In the future, it is expected that amino acid analysis will be used to certify the concentration 
of purified protein reference materials and that trypsin digestion-isotope dilution-mass 
spectrometry with well-characterized isotope-labeled protein or peptide internal standards 
(as described in this document) will become the reference method procedures used to 
establish the concentration of proteins in matrix-matched reference materials. Once the field 
establishes assays using enzymatic digestion-isotope dilution-mass spectrometry as 
reference method procedures, and once basic researchers, clinical researchers, and clinical 
laboratories more universally adopt quantitative targeted molecular assays such as validated 
MRM methods for general protein quantification, the field will have taken an important step 
toward the more rapid translation of replicable experiments to the care of patients.
Disclaimer
Certain commercial equipment, instruments, and materials are identified in this paper to 
adequately specify the experimental procedures. Such identification does not imply 
recommendation or endorsement nor does it imply that the equipment, instruments, or 
materials are necessarily the best available for the purpose.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Example of a Recommended Assessment of Peptides
MALDI-MS spectra of lower purity (A) and high-purity (B) peptides. The internal standard 
was a synthetic peptide (Glu-Fib).
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Figure 2. Summary of the stability and efficiency of hydrolysis of the natural amino acids
Each amino acid is characterized with respect to stability in acid, stability during storage, 
and efficient hydrolysis. Green indicates that the amino acid is favorably stable or 
hydrolysable. Red indicates instability. Yellow is used to highlight three hydrophobic amino 
acids that can affect hydrolysis.
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Figure 3. Evaluation of peptide concentration on stability of signal over time
The peak areas (normalized to time zero) from two representative peptides were plotted 
versus autosampler storage time (hours) to show that storing the peptides at higher 
concentration can minimize the loss of peptide signals, presumably attributed to adsorption 
of the peptides to vials. See Supplemental Materials and Methods for details.
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Figure 4. Effect of autosampler vial material on stability of peptides in a protein digest: plastic, 
non-deactivated glass, deactivated glass
The plastic vial outperforms the two glass vials, as it is associated with only one “unstable” 
peptide. The peptide sequences are sorted by relative hydrophobicity. See Supplemental 
Materials and Methods for details.
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Figure 5. Evaluation of freeze-thaw effect
Mean values of total peak area from triplicate injections are plotted for all detected peptides. 
Error bars show standard deviation. (A) Low abundance, medium abundance, and high 
abundance peptide signals are plotted in separate boxes; similar peak areas of the peptide 
were observed after storage under three conditions: refrigerator storage (‘control’), freezer 
storage with one freeze-thaw cycle, and ten freeze-thaw cycles. (B) Coefficient of variation 
(CV) is plotted as a function of peptide sequence. Peptides are plotted on the x-axis in order 
of increasing retention time. See Supplemental Materials and Methods for details.
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Table 1
Guidelines for peptide selection for MRM targeted assays
Filtering Criteria Description
Uniqueness (analyte specificity) Peptides must be unique in sequence to the gene product or proteoform
1 of interest to enable 
specificity of the assay.
Peptide Length Typically 7-20 AA
Observability by MS
Ideally, peptides should be empirically identified in MS experiments using the instrument on which the 
method is expected to be developed. Frequency of observation, selectivity, and MS signal intensity can 
be used to rank order in cases where multiple peptides meet the in silico selection criteria.
Hydropathy
Extremely hydrophobic peptides can be problematic due to solubility issues, and extremely hydrophilic 
peptides can be problematic due to LC retention time instability. As a general rule, it is best to select 
peptides within an SSRCalc score range of 10-45, see http://hs2.proteome.ca/SSRCalc/SSRCalcX.html.
Reactive Residues (amino acid 
residues that may be susceptible to 
modifications during sample 
preparation)
Avoid these residues if possible, listed in decreasing priority (potential post-translational/preanalytical 
processing issues listed in brackets):
• Cysteine (carbamidomethylation, oxidation, cyclization if N-terminal)
• Methionine (oxidation)
• N-terminal glutamine (pyroglutamic acid formation)
• Asparagine or glutamine when followed by glycine (deamidation)
• Aspartic acid followed by glycine (dehydration) or proline (peptide chain cleavage).
• Tryptophan (oxidation)
• Histidine (additional charge states)
Digestion Parameters
Tryptic peptides generally have an optimal length for analysis and usually form doubly or triply 
charged positive ions (depending on the sequence), which provide useful sequence information through 
MS/MS fragmentation. Peptide sequences containing inhibitory motifs for trypsin that commonly result 
in missed cleavages (e.g., Lys-Lys and Arg-Arg) may display variable digestion yields and should be 
avoided if possible2. Avoid ragged ends (i.e. KK, KR, RR, RK) and possible miss-cleavage sites (i.e. 
KP and RP).
Modification Motifs
Unless the goal is to quantify the posttranslationally modified isoform, peptides near or containing 
potential posttranslational modification sites [e.g. phosphorylation, N-glycosylation (NXS/T)] should 
be avoided where possible, since they may affect assay results by altering the recoverability and/or 
detection of the analyte peptide.
1
Smith, L.M. et al. 2013. Proteoform: a single term describing protein complexity. Nat Methods. 10(3):186-7.
2
Riviere, L. R. and Tempst, P. 2001. Enzymatic Digestion of Proteins in Solution. Current Protocols in Protein Science. 00:11.1:11.1.1–11.1.19.
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Table 2
Pure Peptide Specifications and Methods for Qualification
Description Specification
Amount ≥ 1 mg ordered; up to 5 mg net peptide content confirmed by AAA
Chemical purity > 95%
Isotope
13C, 15N; for doubly charged precursors, use minimum of 6 Da mass delta to unlabeled amino 
acid; for triply charged precursors a minimum of 8-10 Da is recommended
Isotopic purity (atom percent) > 99%
Heavy AA Lys, Arg are recommended in the case of tryptic peptides; other AA may be labeled e.g. Leu, Phe)
Number of heavy AA 0 - 2, depending on sequence and label
Mass difference (relative to unlabeled 
peptide) 6 - 20 Da depending on AA sequence
Location of heavy AA C-terminal Lys or Arg (unless noted otherwise)
AA's to be chemically modified as part of 
peptide synthesis
All Cys as carbamidomethylated Cys; incorporate posttranslational modifications if the goal is 
to quantify the modified peptide (e.g., phosphorylation at Ser, Thr, and/or Tyr; acetylation; 
epigenetic modifications on Lys/Arg)
Delivery time 4 – 6 weeks
Formulation – up to first 1mg of peptide 5 – 30 % acetonitrile/0.1-1% formic acid at approximate concentration of 0.5 - 2 nmol/μL (500-2000 μM). Aliquots of this solution are used for AAA.
Formulation - remaining mg of peptide dry powder (preferably in 0.1 - 1 mg aliquots) stored under argon/nitrogen or in a desiccator, at -20C or lower for longer term storage (> 6 mos)
Purification method preparative RP HPLC
QC – 1 (LC-UV) analytical RP HPLC chromatogram (determine % purity)
QC – 2 (MS or LC-MS/MS) MALDI, ESI spectrum (mass ID confirmation)orMS/MS (label + sequence verification)
QC – 3 (Amino acid analysis, AAA) Concentration (pmol/μL or μM)Percent variation or percent relative error from expected AA composition (% )
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Table 3
Lower Purity Peptide Specifications and Methods for Qualification
Description Specification
Amount ≥ 100 μg, by weight or maximum possible quantity by AAA
Chemical purity > 50%, the peptide should be the highest peak in the HPLC chromatogram
Isotopic atoms
13C, 15N; for doubly charged precursors, use minimum of 6 Da mass delta to unlabeled 
amino acid; for triply charged precursors a minimum of 8-10 Da is recommended
Isotopic purity (atom percent) > 99%
Heavy AA Lys, Arg are recommended in the case of tryptic peptides; other AA may be labeled e.g. Leu, Phe)
Number of heavy AA 0 - 2, depending on sequence and label
Mass difference (relative to unlabeled peptide) 7 - 20 Da depending on AA sequence
Location of heavy AA C-terminal Lys or Arg (unless noted otherwise)
AA's to be chemically modified as part of 
peptide synthesis
All Cys alkylated (e.g., carbamidomethylated Cys); phosphorylation of specific Ser, Thr, 
and/or Tyr
Delivery time 2 – 4 weeks
Formulation – up to first 1mg of peptide 5 – 30 % acetonitrile/0.1-1% formic acid at estimated (by dry wt.) concentration of 1 mg/mL.
Formulation - remaining mg of peptide none
Purification method none, or SPE only
QC – 1 (LC-UV) LC-UV chromatogram (% purity)Performed and assessed by submitting laboratory.
QC – 2 (MS or LC-MS/MS) MALDI, ESI spectrum (mass ID confirmation)orMS/MS (label + sequence verification)
QC – 3 (AAA) None until identification of desired peptide as major species by MS
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Table 4
Amino acid composition of high and lower purity preparations of a peptide 
(FYGAEIVSALEYLHSR)
Amino Acid Expected High Purity1 Lower Purity1
Ala 2 2.0 2.0
Arg 1 1.0 1.3
Asx 0 n.d. n.d.
Glx 2 2.0 2.1
Gly 1 1.0 0.9
His 1 1.1 1.3
Ile 1 0.9 0.9
Leu 2 2.1 2.5
Lys 0 n.d. n.d.
Phe 1 1.0 0.7
Pro 0 n.d. n.d.
Ser 2 1.9 2.2
Thr 0 n.d. n.d.
Tyr 2 2.0 2.0
Val 1 1.0 1.1
1
The average of four AAA determinations with coefficient of variation = 7.6% and 4.8% for the high and lower purity peptides, respectively.
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Table 5
Important information to be obtained from commercial labs regarding their AAA 
methods
Assay characteristic Questions to ask
Hydrolysis How do you hydrolyze your peptides? What hydrolysis reagents do you use? At what temperature do you incubate the reactions and for how long?
Internal standards
What standards do you use for:
1 Hydrolysis
2 Instrument validation
3 Amino Acid Calibration
When do you add your internal standards? How many isotope labeled analog compounds are included in the 
internal standards?
Method of amino acid 
separation Do you use chromatography or electrophoresis to separate the amino acids?
Method of detection How do you detect resolved amino acids (e.g., UV using a fluorophore or MS)?
Calibration materials How do you calibrate your assay? How often the calibration is performed? How many calibration standards are used for the calibration?
Quality controls How do you assess the quality of the sample hydrolysis? What quality control materials are used in your assay?
Precision What is the precision of your assay? How did you determine the precision of your assay? How do you continue to monitor the precision of your assay?
Accuracy and traceability
How did you establish the accuracy of your method? Is your assay traceable to NIST or another reference 
material? How do you ensure continued traceability? Is the laboratory participating in external quality 
control program?
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Table 7
Recommended guidelines for peptide storage and handling
Description Specification
Artifacts due to chemical 
modification or 
degradation
• Limit air exposure of peptides in solution
• Use an inert blanket gas in storage tubes
• Use amber or dark storage tubes for photochemically active sequences
• Avoid multiple freeze-thaws
Duration of storage
• Short-term (≤ 3 months): High concentration (1 – 100 pmol/μL) liquid solution at 4 °C or frozen 
solution at -20 to -80 °C
• Medium-term (3 months – 1 year; peptide-dependent): Frozen solution at high concentration
• Long-term (> 1 year): Lyophilized at -20 to -80 °C
• Concentrated stock solution (0.5-2 nmol/μL): Storage duration depends on peptide
• Short-term: Working solutions (1-100 pmol/μL)
Reconstitution
• General reconstitution solution: 5 % acetonitrile/0.1-1 % formic acid
• Troubleshooting: Increase organic solvent and adjust pH
• Obtain AAA concentration and UV absorbance data
Minimization of non-
specific adsorption
• Add peptides directly to diluent fluid instead of tube walls
• Rinse pipette tip several times with peptide solution prior to aspirating final volume
• Use new pipette tip for each dilution
• Maintain relatively high concentrations (0.5-2 nmol/μL)
Storage vessels
• Silanized glass vials
• Polypropylene vials or plates with modified plastic surfaces
• Wash vials and tubes with same solution being used for peptides, and examine plastics for residual 
plasticizers
Evaluation of peptide 
stability
• Condition peptides to autosampler tray temperature prior to injection (consider temperatures above 4° 
C, which can improve stability)
• Quantify reconstituted peptides by AAA and benchmark the concentration using UV absorbance
• Characterize solubility and adsorption behavior through UV absorbance of a series of dilutions or 
replicates and repeated injection on the LC-MS system
• Evaluate peptide stability for six temperature- and time-related conditions as outlined in Assay 
Development Guidelines available on CPTAC Assay Portal (https://assays.cancer.gov/)
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Table 8
Sources and distributors of reference materials
Institution URL
National Institutes of Standards and Technology www.nist.gov/srm/index.cfm
Institute for Materials and Measurements ec.europa.eu/jrc/en/reference-materials
Joint Committee for Traceability in Laboratory Medicine www.bipm.org/jctlm
World Health Organization www.who.int/bloodproducts/catalogue
LGC Standards www.lgcstandards.com/Catalogues
National Institute for Biological Standards and Control www.nibsc.org/products/brm_product_catalogue.aspx
Sigma-Aldrich www.sigmaaldrich.com
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